V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160012634 | 160006085 | 1.71 | 74.8 | Palliative (P) | 2019-09-07 | 2019-09-09 | CISPLATIN + ETOPOSIDE | 02 | N | NIVOLUMAB | 101070360 |
| 160012638 | 160006086 | 1.76 | 75.65 | Neo-adjuvant (N) | 2016-01-09 | 2016-01-15 | Doxorubicin + Olaratumab | 2 | N | DOXORUBICIN + IFOSFAMIDE | 101712904 |
| 160012639 | 160006087 | null | 49.2 | null | 2018-11-19 | 2018-12-05 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101235365 |
| 160012640 | 160006088 | 1.85 | 106 | Disease modification (D) | null | 2016-09-26 | null | N | N | DOXORUBICIN + IFOSFAMIDE | 101024644 |
| 160012641 | 160006089 | 1.89 | 93.6 | Palliative (P) | 2019-09-09 | 2019-09-10 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101852267 |
| 160012643 | 160006090 | 1.76 | 56.95 | null | null | null | Pemetrexed | 02 | N | DOXORUBICIN | 100450596 |
| 160012644 | 160006091 | null | null | Palliative (P) | 2018-11-01 | 2018-11-02 | Cisplatin + Pemetrexed | 2 | null | CISPLATIN + PEMETREXED | 101436230 |
| 160012645 | 160006092 | 1.65 | 54.1 | Palliative (P) | 2020-08-09 | 2020-08-09 | Doxorubicin + Ifosfamide | 02 | N | IVA | 100023522 |
| 160012647 | 160006093 | 1.76 | 54.7 | Neo-adjuvant (N) | 2016-03-16 | 2016-03-29 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101140043 |
| 160012648 | 160006094 | 1.68 | 82.8 | Curative (C) | 2018-08-06 | 2018-08-14 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101807679 |
| 160012652 | 160006095 | 1.82 | 83.5 | null | 2019-02-12 | 2019-03-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100922726 |
| 160012653 | 160006096 | 1.71 | 63.6 | null | 2022-02-02 | 2022-02-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100658194 |
| 160012654 | 160006097 | 1.63 | 113 | Neo-adjuvant (N) | null | 2018-12-29 | GC Int Guide Excranial GermCell JEB | 02 | null | EW EUROEWING 2012 ARM B VDC | 100211597 |
| 160012655 | 160006098 | 1.7 | 68.5 | Palliative (P) | 2016-05-27 | 2016-06-03 | Trial Unspecified | 02 | N | DOXORUBICIN | 101384647 |
| 160012656 | 160006099 | 1.68 | 69.7 | Palliative (P) | 2019-12-02 | 2019-12-02 | ETOP 13-18 BEAT-meso Trial | 2 | N | DOXORUBICIN + IFOSFAMIDE | 100203285 |
| 160012657 | 160006100 | 1.68 | 65.55 | null | 2017-11-13 | 2017-11-13 | Doxorubicin + Olaratumab | 02 | N | IRINOTECAN + CISPLATIN + MITOMYCIN | 101517994 |
| 160012658 | 160006101 | 1.66 | 110 | Neo-adjuvant (N) | 2013-12-21 | 2014-01-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101800343 |
| 160012661 | 160006102 | 1.73 | 68 | Curative (C) | 2017-08-31 | 2017-09-18 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101635858 |
| 160012662 | 160006103 | null | null | null | 2020-01-10 | 2020-01-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100507437 |
| 160012663 | 160006104 | 1.72 | 76 | Curative (C) | 2018-03-10 | 2018-03-10 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101221667 |
| 160012664 | 160006105 | 1.86 | 45.2 | Neo-adjuvant (N) | 2017-03-22 | 2017-03-30 | VIDE | 02 | N | NOT MATCHED | 100047941 |
| 160012667 | 160006106 | 1.57 | 40.9 | Neo-adjuvant (N) | 2016-10-24 | 2016-10-25 | Paclitaxel 7 day | 02 | N | DOXORUBICIN | 101604111 |
| 160012668 | 160006107 | 1.55 | 90.4 | Curative (C) | 2019-01-21 | 2019-01-28 | null | N | N | TRIAL UNSPECIFIED | 100138619 |
| 160012672 | 160006108 | 1.73 | 83.7 | Palliative (P) | 2018-03-13 | 2018-03-13 | DOXORUBICIN | 02 | N | IBRUTINIB | 100905528 |
| 160012675 | 160006109 | 1.82 | 82.8 | Palliative (P) | 2020-01-05 | 2020-01-18 | CARBOPLATIN + ETOPOSIDE | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100814415 |
| 160012678 | 160006110 | 1.82 | 87.5 | Palliative (P) | 2015-11-21 | 2015-11-27 | Trial Unspecified | 01 | N | TRIAL UNSPECIFIED | 100655033 |
| 160012680 | 160006111 | 1.56 | 83.8 | Disease modification (D) | 2017-08-16 | 2017-08-20 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100099971 |
| 160012681 | 160006112 | 1.59 | 70.9 | Palliative (P) | 2019-05-11 | 2019-06-03 | Doxorubicin + Ifosfamide | 02 | N | LIPOSOMAL DOXORUBICIN | 101498989 |
| 160012682 | 160006113 | 1.65 | 77.5 | Palliative (P) | 2018-07-04 | 2018-07-21 | Doxorubicin + Olaratumab | 02 | N | STS NON-RHABDO EPSSG 2005 | 100871699 |
| 160012683 | 160006114 | 1.62 | 60.2 | Palliative (P) | 2019-03-26 | 2019-04-14 | Doxorubicin + Olaratumab | N | N | DOXORUBICIN + IFOSFAMIDE | 100519973 |
| 160012684 | 160006115 | null | null | Neo-adjuvant (N) | 2018-05-01 | 2018-05-07 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101816965 |
| 160012685 | 160006116 | 1.59 | 75.1 | Palliative (P) | 2016-04-21 | 2016-04-24 | Cisplatin + Doxorubicin | 02 | N | PACLITAXEL | 101772382 |
| 160012686 | 160006117 | 1.59 | 99.5 | Palliative (P) | null | 2020-02-25 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100422220 |
| 160012690 | 160006118 | 1.94 | 63.4 | Palliative (P) | 2018-08-22 | 2018-08-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101583345 |
| 160012691 | 160006119 | 1.72 | 69.4 | Disease modification (D) | 2018-02-19 | 2018-03-06 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100129146 |
| 160012693 | 160006120 | 1.64 | 45 | Disease modification (D) | 2015-05-02 | 2015-05-03 | Liposomal Doxorubicin (Caelyx) | 01 | N | HYDROXYCARBAMIDE | 101055419 |
| 160012697 | 160006121 | 1.57 | 89.9 | Neo-adjuvant (N) | 2016-11-06 | 2016-11-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101395997 |
| 160012698 | 160006122 | 1.61 | 80 | Curative (C) | 2019-10-15 | 2019-10-26 | Doxorubicin + Ifosfamide | N | N | IMATINIB | 100362685 |
| 160012700 | 160006123 | 1.53 | 45 | Palliative (P) | null | 2019-09-05 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101150558 |
| 160012702 | 160006124 | 1.79 | 66 | Palliative (P) | 2021-03-07 | 2021-03-27 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 02 | N | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 101398089 |
| 160012703 | 160006125 | 1.62 | 74 | Palliative (P) | 2019-03-28 | 2019-03-28 | Cyclophosphamide + Vincristine | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101660855 |
| 160012704 | 160006126 | 1.61 | 111.5 | Palliative (P) | 2018-07-08 | 2018-07-08 | Olaratumab | 02 | N | PAZOPANIB | 101538334 |
| 160012705 | 160006127 | 0 | 78.2 | Curative (C) | 2017-10-23 | 2017-10-31 | DACARBAZINE + DOXORUBICIN | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100909352 |
| 160012706 | 160006128 | 1.65 | 83.2 | Neo-adjuvant (N) | 2018-08-14 | 2018-08-16 | Cisplatin + Pemetrexed | null | Y | CISPLATIN + PEMETREXED | 101858815 |
| 160012708 | 160006129 | 1.9 | 57 | Palliative (P) | 2019-06-06 | 2019-06-06 | Doxorubicin + Olaratumab | N | N | DOXORUBICIN + IFOSFAMIDE | 100869414 |
| 160012709 | 160006130 | 1.61 | 82.4 | Palliative (P) | 2016-04-03 | 2016-04-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100320128 |
| 160012711 | 160006131 | 1.6 | 70.9 | null | 2018-04-24 | 2018-04-25 | ETOPOSIDE + RITUXIMAB | 02 | N | EW EUROEWING 2012 ARM A VAC | 100265393 |
| 160012714 | 160006132 | 0 | 68 | 03 | 2017-07-22 | 2017-08-16 | EOX | 02 | N | CAPECITABINE | 100605917 |
| 160012717 | 160006133 | 1.8 | 61.5 | Palliative (P) | 2016-04-03 | 2016-04-04 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101399716 |
| 160012719 | 160006134 | 1.75 | 52 | Palliative (P) | 2018-03-31 | 2018-03-31 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100454470 |